Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation

BACKGROUND: Tripeptide tyroserleutide (YSL) is a novel small molecule anti-tumor polypeptide that has been shown to inhibit the growth of human liver cancer cells. In this study, we investigated the effects of YSL plus doxorubicin on the growth of human hepatocellular carcinoma BEL-7402 cells that h...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Zhu, Zhi-feng, Chen, Li-juan, Lu, Rong, Jia, Jing, Liang, Yu, Xu, Qiong, Zhou, Chun-lei, Wang, Li, Wang, Song, Yao, Zhi
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2008
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2601048/
https://ncbi.nlm.nih.gov/pubmed/19025669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-8-342
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky